John O'Reardon, MD

EXPERT Q&A

Practical Issues in Using Transcranial Magnetic Stimulation

January 1, 2009

TCPR-January-2009-TMS_JohnO'ReadonMD_Headshot.png

John O'Reardon, MD. Associate Professor of Psychiatry, University of Pennsylvania Health System.

Dr. O’Reardon has disclosed that he has received research grants from Neuronetics, Cyberonics, Cerex Biopharma, and Pfizer, and is on the speaker's bureaus of Eli Lilly and Bristol-Myers Squibb. Dr. Carlat has found that there is no evidence of commercial bias in this educational activity.

Dr. O’Reardon, the FDA recently approved TMS for depression. Can you clarify exactly what this approval was for?

Dr. John O’Reardon on Antidepressant Augmentation

January 1, 2004

John O'Reardon, MD

John O’Reardon, MD. Medical Director, Treatment Resistant Depression Clinic Associate Professor of Psychiatry, University of Pennsylvania School of Medicine

Dr. O'Reardon, you had mentioned at the end of our last interview (see TCR, Vol. 1, No. 1) some of the augmentation and combination strategies that you like to use in your clinic but we didn't have time to get into the actual specifics of these. To begin with, how do you decide when to augment? What kinds of drug failures do you try to establish?